Cevidoplenib dimesylate|CAS 2043659-93-2|DC Chemicals

Cas No.:	2043659-93-2
Chemical Name:	Unii-B6NX06SK0J
Synonyms:	B6NX06SK0J;Cevidoplenib dimesilate;Cevidoplenib dimesylate;Methanone, cyclopropyl(5-((4-(4-(((4S)-4-hydroxy-2-isoxazolidinyl)methyl)-3-methyl-1H-pyrazol-1-yl)-2-pyrimidinyl)amino)-1-methyl-1H-indol-3-yl)-, methanesulfonate (1:2);Unii-B6NX06SK0J
SMILES:	S(C)(=O)(=O)O.S(C)(=O)(=O)O.O=C(C1=CN(C)C2C=CC(=CC1=2)NC1N=CC=C(N=1)N1C=C(C(C)=N1)CN1C[C@@H](CO1)O)C1CC1
Formula:	C₂₇H₃₅N₇O₉S₂
M.Wt:	665.738303422928
Purity:	>98%
Sotrage:	2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO

Cat. No.	Product name	Field of application
DC48364	Sovleplenib	Sovleplenib is a highly potent inhibitor of spleen tyrosine kinase (Syk), derived from the innovative research disclosed in patent WO2012167733 A1. This compound demonstrates significant potential in modulating Syk-mediated signaling pathways, offering a promising therapeutic approach for conditions where Syk activity plays a critical role. Its development underscores the ongoing advancements in targeted kinase inhibition, providing a valuable tool for both research and potential clinical applications in immune-related and inflammatory diseases.
DC48025	Cevidoplenib dimesylate	Cevidoplenib is an orally available inhibitor of spleen tyrosine kinase (Syk), with potential anti-inflammatory and immunomodulating activities.
DC40848	SRX3207	SRX3207 is an orally active and first-in-class dual Syk/PI3K inhibitor. SRX3207 possesses anti-tumor activity.
DC28254	Lanraplenib monosuccinate	Lanraplenib monosuccinate (GS-9876 monosuccinate) is a highly selective and orally active SYK inhibitor (IC50=9.5 nM) in development for the treatment of inflammatory diseases. Lanraplenib monosuccinate (GS-9876 monosuccinate) inhibits SYK activity in platelets via the glycoprotein VI (GPVI) receptor without prolonging bleeding time (BT) in monkeys or humans.